Merck has signed a multi-year collaboration agreement with privately-held NGM Biopharmaceuticals to develop novel biologic therapies in a wide range of therapeutic areas. NGM said that it has entered a five-year collaboration to research, develop and commercialize drugs that treat diabetes, obesity and nonalcoholic steatohepatitis (NASH). Merck will pay NGM …